

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6648949

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID L MCELLIGOTT	03/21/2021
ELI LILLY AND COMPANY	03/30/2021
LOXO ONCOLOGY, INC.	03/26/2021
SCHRODINGER, L.L.C.	03/24/2021
RECEIVING PARTY DATA	
Name:	PETRA PHARMA CORPORATION
Street Address:	450 E. 29TH STREET
Internal Address:	SUITE 506
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10016
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17221209
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@lilly.com
Correspondent Name:	ELI LILLY AND COMPANY
Address Line 1:	P. O. BOX 6288
Address Line 2:	PATENT DIVISION
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X22826
NAME OF SUBMITTER:	PATRICIA FOOR
SIGNATURE:	/Patricia Foor/
DATE SIGNED:	04/09/2021
Total Attachments: 9	
source=X22826AssignmentMCELLIGOTTtoPetra#page1.tif	

source=X22826AssignmentMCELLIGOTTtoPetra#page2.tif
source=X22826AssignmentMCELLIGOTTtoPetra#page3.tif
source=X22826AssignmentLILLYtoPetra#page1.tif
source=X22826AssignmentLILLYtoPetra#page2.tif
source=X22826AssignmentLOXOtoPetra#page1.tif
source=X22826AssignmentLOXOtoPetra#page2.tif
source=X22826AssignmentSCHRODINGER_LLCToPetra#page1.tif
source=X22826AssignmentSCHRODINGER_LLCToPetra#page2.tif

ASSIGNMENT

WHEREAS, I,

David L. MCELLIGOTT, Bothell, WA

Citizenship: United States

am a co-inventor, including at least the following person(s):

Erin Danielle ANDERSON, Boulder, CO	Citizenship: United States
Sean Douglas ARONOW, Boulder, CO	Citizenship: United States
Nicholas A. BOYLES, Hillsboro, OR	Citizenship: United States
Markus K. DAHLGREN, Shelton, CT	Citizenship: Sweden
Shulu FENG, Ridgewood, NJ	Citizenship: China
Aleksey I. GERASYUTO, Flemington, NJ	Citizenship: United States
Eugene R. HICKEY, Danbury, CT	Citizenship: United States
Thomas Combs IRVIN, Erie, CO	Citizenship: United States
Edward A. KESICKI, New York, NY	Citizenship: United States
Anke KLIPPEL-GIESE, Princeton, NJ	Citizenship: Germany
Jennifer Lynn KNIGHT, Jersey City, NJ	Citizenship: Canada
Gabrielle R. KOLAKOWSKI, Longmont, CO	Citizenship: United States
Manoj KUMAR, Longmont, CO	Citizenship: India
Katelyn Frances LONG, Lafayette, CO	Citizenship: United States
Christopher Glenn MAYNE, Boulder, CO	Citizenship: United States
Johnathan Alexander MCLEAN, Indianapolis, IN	Citizenship: United States
Loredana PUCA, New York, NY	Citizenship: Italy
Kannan Karukurichi RAVI, Fords, NJ	Citizenship: India
Daniel Lee SEVERANCE, San Diego, CA	Citizenship: United States
Michael Brian WELCH, Westminster, CO	Citizenship: United States
Tien WIDJAJA, Lafayette, CO	Citizenship: United States

of an invention that is the subject of a patent application ("Application") which is entitled
ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE, for filing:

- ☒ in the United States Patent and Trademark Office on April 2, 2021
and accorded Serial Number 17/221209,
- ☐ in the _____ on _____
and accorded Serial Number _____,
- ☐ in the Spanish Patent Office as a European Application on _____
and accorded Serial Number _____,
- ☒ as an international application under the Patent Cooperation Treaty ("PCT"), with
United States Patent and Trademark Office acting as Receiving Office on
April 2, 2021 and accorded Serial Number PCT/US2021/025521
- ☐ as an international application under the Patent Cooperation Treaty ("PCT"), with
The State Intellectual Property Office (SIPO) of China acting as Receiving Office on
_____ and accorded Serial Number _____,

both of which claim the benefit of priority application Serial Number 63/005096,
filed April 3, 2020.

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS PETRA PHARMA CORPORATION ("ASSIGNEE"), having a place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016**, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to Petra Pharma Corporation, its successors and assigns, my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Petra Pharma Corporation for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to Petra Pharma Corporation not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with Petra Pharma Corporation that upon request I and they will, without further consideration than that now paid, but at the expense of Petra Pharma Corporation: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Petra Pharma Corporation any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Petra Pharma Corporation, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Petra Pharma Corporation or its nominees, in the United States and in all other countries where Petra Pharma Corporation may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Petra Pharma Corporation and to vest and confirm in Petra Pharma Corporation or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

3/21/2021
Date

David L. Mcelligott
DAVID L. MCELLIGOTT

ACCEPTED AS OF THE DATE ABOVE BY:

Brad Crawford
Authorized Representative
for PETRA PHARMA CORPORATION

Printed Name Brad Crawford
Title Patent Counsel

ASSIGNMENT

WHEREAS, ELI LILLY AND COMPANY, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285, by virtue of an assignment between Johnathan Alexander MCLEAN and Eli Lilly and Company, is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on April 2, 2021
and accorded Serial Number 17/221209

☐ in the _____ on _____
and accorded Serial Number _____

☐ in the Spanish Patent Office as a European Application on _____
and accorded Serial Number _____

☒ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on April 2, 2021 and accorded Serial Number PCT/US2021/025521.

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _____ and accorded Serial Number _____

which claims the benefit of priority application Serial Number 63/005096, filed April 3, 2020

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION, a subsidiary of Eli Lilly and Company, having its principal place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; **AND WHEREAS**, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.


NOW, THEREFORE, pursuant an agreement between ASSIGNEE and ELI LILLY AND COMPANY, or other good and valuable consideration, the receipt of which is hereby acknowledged, ELI LILLY AND COMPANY hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns ELI LILLY AND COMPANY's entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the

Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by ELI LILLY AND COMPANY had this Assignment and sale to ASSIGNEE not been made.

ELI LILLY AND COMPANY authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.


For ASSIGNEE and its legal representative, ELI LILLY AND COMPANY covenants and agrees that ELI LILLY AND COMPANY has not granted to any others any license to make, use or sell any of such inventions, that ELI LILLY AND COMPANY's right, title and interest in such inventions has not been encumbered, that ELI LILLY AND COMPANY has good right and title to sell and assign the same, and that ELI LILLY AND COMPANY will not execute any instrument in conflict therewith.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.


Authorized Representative for
ELI LILLY AND COMPANY

Printed Name Steven P. Caltrider
Title Vice President and General Patent Counsel
Date 3/30/2021

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from ELI LILLY AND COMPANY without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.


Authorized Representative for
PETRA PHARMA CORPORATION

Printed Name Bradley W. Crawford
Title Patent Counsel
Date 30 March 2021

ASSIGNMENT

WHEREAS, LOXO ONCOLOGY, INC., a subsidiary of Eli Lilly and Company, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285 and a correspondence address of c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 by virtue of an assignment between Erin Danielle ANDERSON, Sean Douglas ARONOW, Thomas Combs IRVIN, Edward A. KESICKI, Anke KLIPPEL, Gabrielle R. KOLAKOWSKI, Manoj KUMAR, Katelyn Frances LONG, Christopher Glenn MAYNE, Loredana PUCA, Kannan Karukurichi RAVI, Michael Brian WELCH, Tien WIDJAJA and LOXO ONCOLOGY, INC., is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on April 2, 2021
and accorded Serial Number 17/221209

☐ in the _____ on _____
and accorded Serial Number _____

☐ in the Spanish Patent Office as a European Application on _____
and accorded Serial Number _____

☒ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office on April 2, 2021 and accorded Serial Number PCT/US2021/025521

☐ as an international application under the Patent Cooperation Treaty ("PCT"), with The State Intellectual Property Office (SIPO) of China acting as Receiving Office on _____ and accorded Serial Number _____

which claims the benefit of priority application Serial Number 63/005096, filed April 3, 2020

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION ("ASSIGNEE"), having a place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; **AND WHEREAS**, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.

NOW, THEREFORE, pursuant to an agreement between ASSIGNEE and LOXO ONCOLOGY, INC., or other good and valuable consideration, the receipt of which is hereby acknowledged, LOXO ONCOLOGY, INC. hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns LOXO ONCOLOGY, INC.'s entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations.

continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by LOXO ONCOLOGY, INC. had this Assignment and sale to ASSIGNEE not been made.

LOXO ONCOLOGY, INC. authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNEE and its legal representative, LOXO ONCOLOGY, INC. covenants and agrees that LOXO ONCOLOGY, INC. has not granted to any others any license to make, use or sell any of such inventions, that LOXO ONCOLOGY, INC.'s right, title and interest in such inventions has not been encumbered, that LOXO ONCOLOGY, INC. has good right and title to sell and assign the same, and that LOXO ONCOLOGY, INC. will not execute any instrument in conflict therewith.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.


Authorized Representative for
LOXO ONCOLOGY, INC.

Printed Name Michael R. Asam
Title Assistant General Patent Counsel
Date 26-Mar-2021

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from LOXO ONCOLOGY, INC. without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.


Authorized Representative for
PETRA PHARMA CORPORATION

Printed Name Bradley W. Crawford
Title Patent Counsel
Date 30 March 2021

ASSIGNMENT

WHEREAS, Schrodinger, L.L.C., 120 West 45th Street, 17th Floor, New York, NY 10036 by virtue of an assignment between Schrodinger, Inc. and **Schrodinger, L.L.C.**, is the Assignee of the right, title and interest in an invention that is the subject of a patent application ("Application") which is entitled **ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE**, for filing:

☒ in the United States Patent and Trademark Office on April 2, 2021
and accorded Serial Number 17/221209,

☐ in the _____ on _____
and accorded Serial Number _____,

☐ in the Spanish Patent Office as a European Application on _____
and accorded Serial Number _____,

☒ as an international application under the Patent Cooperation Treaty ("PCT"),
with United States Patent and Trademark Office acting as Receiving Office on
April 2, 2021 and accorded Serial Number PCT/US2021/025521,

☐ as an international application under the Patent Cooperation Treaty ("PCT"),
with The State Intellectual Property Office (SIPO) of China acting as Receiving
Office on _____ and accorded Serial Number _____,

which both claim the benefit of priority application Serial Number 63/005096, filed
April 3, 2020.

I hereby give permission to insert above the serial number(s) and filing date(s) for the application when known.

WHEREAS, PETRA PHARMA CORPORATION ("ASSIGNEE"), having a place of business at **450 E 29TH ST., SUITE 506, NEW YORK, NY 10016** wishes to acquire the entire right, title and interest in and to all invention disclosed in such Application, and in, to and under any Letters Patent which may be obtained to said invention; AND WHEREAS, accordingly the parties hereto are executing this Deed of assignment to record in writing the terms and conditions of their understanding.

NOW, THEREFORE, pursuant an agreement between ASSIGNEE and **SCHRODINGER, L.L.C.**, or other good and valuable consideration, the receipt of which is hereby acknowledged, **SCHRODINGER, L.L.C.** hereby sells, assigns, transfers and sets over unto ASSIGNEE, its successors and assigns **SCHRODINGER, L.L.C.**'s entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates;

and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by the ASSIGNEE for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by **SCHRODINGER, L.L.C.** had this Assignment and sale to ASSIGNEE not been made.

SCHRODINGER, L.L.C. authorizes and requests the Commissioner of Patents and Trademarks of the United States, and any foreign equivalent thereof, to issue any such Letters Patent which may be granted on the Application to ASSIGNEE as assignee of the entire right, title and interest therein and thereto.

For ASSIGNEE and its legal representative, **SCHRODINGER, L.L.C.** covenants and agrees that **SCHRODINGER, L.L.C.** has not granted to any others any license to make, use or sell any of such inventions, that **SCHRODINGER, L.L.C.**'s right, title and interest in such inventions has not been encumbered, that **SCHRODINGER, L.L.C.** has good right and title to sell and assign the same, and that **SCHRODINGER, L.L.C.** will not execute any instrument in conflict therewith.

IN WITNESS WHEREOF I have executed this assignment on the date indicated below.

(Printed Name)
Ramy Farid

Authorized Representative for
SCHRODINGER, L.L.C.

Printed Name Ramy Farid

Title President & CEO

Date March 24, 2021

PETRA PHARMA CORPORATION, the assignee, hereby accepts the assignment from **SCHRODINGER, L.L.C.** without any restrictions, and with all rights and obligations derived therefrom. Accepted as of the date above.

Bradley W. Crawford
Authorized Representative for
PETRA PHARMA CORPORATION

Printed Name Bradley W. Crawford

Title Patent Counsel

Date 30 March 2021